Shots:
- HUTCHMED has initiated P-III portion of P-II/III trial of the combination of surufatinib, camrelizumab, nab-paclitaxel & gemcitabine (S+C+AG) as the 1L treatment of metastatic PDAC in China, with the first patient receiving the dose on Dec 30, 2025
- Trial will evaluate the combination against nab-paclitaxel + gemcitabine in ~400 PDAC adults who have not previously received systemic anti-tumor therapy, assessing OS as 1EP, plus PFS, ORR, DoR, DCR, QoL & safety as 2EPs
- In the P-II portion (n=62) at 8.15mos. mFU (data cut off: Jul 24, 2025), S+C+AG improved mPFS to 7.20 vs 5.52mos. with AG, reduced risk of progression or death by 50.1%, improved ORR (67.7% vs 41.9%) & DCR (93.5% vs 71%), & showed a favorable OS trend (not reached vs 8.48mos.) despite immature data
Ref: Globenewswire | Image: HUTCHMED |Press Release
Related News: HUTCHMED Reports NMPA’s NDA Acceptance with Priority Review of Savolitinib for Gastric Cancer Patients with MET Amplification
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
